Kyntra Bio (KYNB) Accumulated Expenses (2014 - 2026)

Kyntra Bio has reported Accumulated Expenses for 13 years, with the latest figure at $17.3 million in Q1 2026.

• Quarterly Accumulated Expenses fell 50.91% year-over-year to $17.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.3 million (down 50.91% YoY) and the FY2025 annual result came in at $20.2 million, down 67.47% from the prior year.
• Accumulated Expenses retreated to $17.3 million in Q1 2026 per KYNB's latest filing, from $20.2 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $219.8 million in Q4 2022 and troughed at $11.5 million in Q1 2024.
• A 5-year average of $113.3 million and a median of $133.0 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses soared 9889.68% in 2022, then tumbled 92.68% in 2024.
• Over 5 years, Accumulated Expenses stood at $219.8 million in 2022, then sank by 39.49% to $133.0 million in 2023, then sank by 53.35% to $62.0 million in 2024, then plunged by 67.47% to $20.2 million in 2025, then slipped by 14.09% to $17.3 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $17.3 million, $20.2 million, and $25.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.